Skip to main content

Prosecution history estoppel

The term "prosecution history estoppel" is a legal principle that applies to patent law in the United States. It is also known as "file wrapper estoppel" or "estoppel by prosecution history." Prosecution history estoppel limits the scope of a patent's claims during patent litigation and affects the rights of a patent holder.


Here's an explanation of prosecution history estoppel:


1. Patent Application Process: When an inventor seeks to obtain a patent for an invention, they submit a patent application to the United States Patent and Trademark Office (USPTO). During the examination process, the patent examiner reviews the application and may issue rejections or objections based on prior art or other reasons.


2. Amendments and Arguments: To overcome rejections or objections, the patent applicant may amend the claims of the patent application or make arguments to convince the examiner that the invention is patentable over the prior art. These amendments and arguments become part of the "prosecution history" or "file wrapper" of the patent application.


3. Prosecution History Estoppel: Prosecution history estoppel arises from the principle of "surrender" during patent prosecution. When a patent applicant makes amendments to the claims or makes certain arguments to secure the issuance of the patent, they may be surrendering or giving up claim scope. As a result, they are "estopped" from later asserting a broader claim scope during litigation that encompasses subject matter surrendered during prosecution.


4. Scope of Patent Claims: During patent litigation, if the accused infringer believes that the patent holder is attempting to assert a claim scope that goes beyond what was allowed by the patent examiner during prosecution, the accused infringer may raise the defense of prosecution history estoppel. The accused infringer can argue that the patent holder is estopped from asserting the broader claim scope because of the amendments and arguments made during prosecution.


5. Application and Impact: Prosecution history estoppel is an important principle in patent litigation because it narrows the interpretation and enforcement of patent claims, preventing patent holders from obtaining broader protection than they were initially granted by the patent office.


It's important to note that prosecution history estoppel is specific to the U.S. patent system and may not apply in the same way in other countries with different patent laws and practices. Additionally, the application of prosecution history estoppel can be complex and may require legal expertise and analysis in the context of a particular patent dispute.

Comments

Popular posts from this blog

Pharma Companies HR contact information

Dear viewers of my blog, I am happy to share the HR contact details of Pharmaceutical companies. Contact Details Of Pharma HRs : Zaydus cadila-Goa gajendravernekar@zayduscadila.com 09623458512/08326615143 Teva-Goa Maryann.Braganza@teva.co.in sanjay.pandit@teva.co.in 0832 6685538 Glenmark-Goa Vittal hebbalkar hr executivr - 9923476869 anupbannatti@glenmark-generics.com 09604151586 Watson-Goa Jyosna.bagule@watsonpharm.co.in runa.divkar@watsonpharm.co.in goa@watsonpharm.co.in 0832 6690666/777 Unichem Labs-Goa abhiram.panshikar@unichemlabs.com R&D  suraj.jadhav@unichemlabs.com vikas.parkar@unichemlabs.com Indico-Goa goahplc@Indoco.com varun.keny@indoco.com anand.ingole@Indoco.com 0832 6624109 Encube-Goa hr@encubeethicals.com nidhi.b@encubeethicals.com 8322392223 Torrent pharma-Ahmdabad mayurdesai@torrentpharma.com 9879603921/22/23/24 Emcure-pune RPKulkarni@emcure.co.in           Kishor.Mule@emcure.co.in Rahul.Morgaonkar@emcure.co.in recruitment@em

Novo Nordisk settles with 2 Florida venders of compounded (Semaglutide)Ozempic:

Novo Nordisk settles with 2 Florida venders of compounded Ozempic: Novo Nordisk has arrived at private settlements with two Florida merchants of intensified forms of the uber blockbuster semaglutide therapies Ozempic and Wegovy, the organization said on Friday. In June of last year, Novo recorded brand name encroachment claims against five dealers of knockoff renditions of the GLP-1 medications, which have seen soaring interest to battle weight reduction. Ekzotica Corp's. Restorative Laser Experts Drug Spa in Miami and Effinger Wellbeing's Nuvida Rx Weight reduction in Tallahassee are the initial two organizations to have settled their cases. As indicated by long-lasting directive orders, the dealers will quit utilizing Novo reserve and have consented to reveal for a considerable length of time that intensified variants of the medications have not gone through the security and viability norms expected by the FDA for supported drugs. "The litigants' unlawful showcasing

Hypertension-An Overview

INTRODUCTION: Systemic arterial hypertension is one of the strongest known modifiable risk factors for ischaemic heart disease, stroke, renal failure and heart failure. It remains poorly treated. As an asymptomatic disorder, people are understandably reluctant to accept adverse drug effects in addition to the inconvenience of long-term treatment. In this regard, modern drugs represent an enormous improvement. PATHOPHYSIOLOGY AND SITES OF DRUG ACTION Hypertension is occasionally secondary to some distinct disease. However, most patients with persistent arterial hypertension have essential hypertension. Arterial blood pressure is determined by cardiac output, peripheral vascular resistance and large artery compliance. Peripheral vascular resistance is determined by the diameter of resistance vessels (small muscular arteries and arterioles) in the various tissues. One or more of a ‘mosaic’ of interconnected predisposing factors (including positive family history, obesity and phys